The Medical Letter on Drugs and Therapeutics
In Brief: Hypo- and Hyperglycemia with Gatifloxacin (Tequin)
Download PDF:   US English
Med Lett Drugs Ther. 2006 Mar 13;48(1230):24
 Select a term to see related articles  adverse effects   Antibiotics   fluoroquinolone   fluoroquinolones   Gatifloxacin   hyperglyemia   hypo- and hyperglycemia with gatifloxacin (tequin)   Hypoglycemia   Tequin 

A study now available on the web site of The New England Journal of Medicine (LY Park-Wyllie et al. Outpatient gatifloxacin therapy and dysglycemia in older adults., published online March 1, 2006) reports an increased risk of hypoglycemia (RR 4.3) and hyperglycemia (RR 16.7) with use of gatifloxacin (Tequin), a fluoroquinolone antibiotic. The Medical Letter published an article on this risk in 2003 (vol. 45, page 64); at that time the extent to which other fluoroquinolones carried the same risk was unclear. The recent report indicates that, except for a slightly increased relative risk of hypoglycemia (RR 1.5) with levofloxacin (Levaquin), they do not. Gatifloxacin, levofloxacin, moxifloxacin (Avelox) and gemifloxacin (Factive) are more active than other quinolones against gram-positive organisms such as Streptococcus pneumoniae, including strains highly resistant to penicillin; they are sometimes called "the respiratory quinolones." Given the availability of other drugs with similar in vitro and clinical activity, there is no good reason to continue to use gatifloxacin.

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article